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Abbreviations 
AP-1 activator protein-1 
bFGF basic fibroblast growth factor 
bp base pair 
CCL2 chemokine (C-C motif) ligand 2 
CCL5 chemokine (C-C motif) ligand 5 
CCR2 chemokine receptor 2 
CWS circumferential wall strain 
cDNA complementary desoxyribonucleic acid 
DNA desoxyribonucleic acid 
DHE dihydroethidium 
D-MEM Dulbecco’s modified Eagle’s medium 
DMSO dimethyl sulfoxyd 
dNTP dosexynucleotide triphosphate 
dODN decoy oligodeoxynucleotide 
EDTA ethylendinitrilo-N, N, N’, N’-tetraacetate 
eNOS endothelial nitric oxide synthetase 
FCS fetal calf serum 
FGF fibroblast growth factor 
FSS fluid shear stress 
GM-CSF granulocyte-macrophage colony stimulating factor 
HIF-1 hypoxia inducible factor-1 
hSMCs human smooth muscle cells 
HUVECs human umbilical vein endothelial cells 
ICAM-1 intracellular adhesion molecule-1 
IL-8 interleukin-8  
LFA-1 lymphocyte function-associated antigen-1 
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Mac-1 macrophage-1 antigen 
MAP mitogen-activated protein 
MCP-1 monocyte chemotactic protein-1 
MMP-2 matrix metalloproteinase-2 
MMP-9 matrix metalloproteinase-9 
mRNA messenger ribonucleic acid 
mSMCs mouse smooth muscle cells 
NF-κB nuclear factor-kappa B 
NO nitric oxide 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PIGF placenta growth factor 
RNA ribonucleic acid 
ROS reactive oxygen species  
RT room temperature 
RT-PCR reverse transcription-polymerase chain reaction 
SEM standard error of the mean 
STAT-1 signal transducer and activator of transcription-1 
TGF-ß transforming growth factor-β 
TIMP-1 tissue inhibitor of matrix-proteases  
TNF-α tumour necrosis factor-α 
TRE triphorbol acetate response elements 
uPA urokinase-type plasminogen activator 
VEGF vascular endothelial growth factor 
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1. Introduction 
1.1. Clinical relevance of arteriogenesis vs. angiogenesis 
Cardiac and peripheral arterial occlusive diseases are the leading cause of death in 
the Western world and often result in the development of ischemia in the affected 
tissues. The treatment of patients with occlusive vascular disease consists of 
lifestyle modifications and pharmacotherapy addressing the risk factors to 
minimize the risk for disease progression and mortality in myocardial infarction 
and stroke. In case of progressing peripheral artery disease, the patient might 
suffer from rest pain and ischemic ulceration and gangrene due to critical limb 
ischemia (Figure 1).  
 
 
Figure 1. Schematic drawing of the pathogenesis in peripheral artery disease (taken 
from Palmer-Kazen, 2003). Symptoms of lower extremity peripheral artery disease 
include pain on walking—intermittent claudication, which is the earliest and most 
frequently present symptom.  
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Symptomatic invasive treatment consists of surgical or endovascular 
revascularization. Unfortunately, about 20% to 30% of patients with critical limb 
ischemia cannot be treated by any of these methods and amputation is often the 
only remaining option (Palmer-Kazen 2003). 
However, it has been known for a long time that patients suffering from ischemic 
vascular diseases can develop collateral vessels bypassing the side of occlusion 
(Fulton 1969). Depending on the initial trigger, growth of blood vessels in adult 
organisms proceeds via two major processes, angiogenesis and arteriogenesis 
(Figure 1) (Semenza 2007). Stimulation and acceleration of these natural 
protective mechanisms have the potential to become an alternative therapeutic 
approach to improve the blood supply to ischemic tissue in case of occlusive 
vascular disease.  
 
Angiogenesis is defined as the formation of new capillaries from existing vessels 
resulting in an improved new capillary network (Risau 1997). It is an important 
component of various normal and pathological conditions such as wound healing, 
fracture repair, folliculogenesis, ovulation, and pregnancy (Buschmann 2001). 
However, if not properly controlled, angiogenesis can also represent a significant 
pathogenic component of tumor growth and metastasis, rheumatic arthritis, and 
retinopathaties.  
Angiogenesis consists of several distinct processes, which include endothelial cell 
migration and proliferation, extracellular proteolysis, endothelial cell 
differentiation, and vascular wall remodelling. In most cases angiogenesis is 
induced by local ischemia, where a decrease in local oxygen tension initiates the 
expression of hypoxia-inducible genes through activation of the transcription factor 
hypoxia inducible factor-1 (HIF-1). Besides the erythropoietin gene, regulating the 
production of erythrocytes in the bone marrow, several angiogenesis-related genes 
are under the control of HIF-1, among which VEGF (vascular endothelial growth 
factor) is the best studied. Synthesized in several splicing variants, VEGF is a 
potent mitogen for endothelial cells and of critical importance for physiological as 
well as pathological angiogenesis, e.g. in neoplastic tumors. VEGF acts like a pro-
angiogenic factor by binding to two tyrosine-kinase receptors VEGFR1 and VEGFR2 
on endothelial cells, whereas VEGFR3 induces lymphangiogenesis upon binding to 
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isoforms VEGF-C and VEGF–D. VEGF induces a complex response in endothelial cells 
including the expression of endothelial nitric oxide synthase (eNOS) and matrix 
metalloproteinases (MMPs) necessary for enhancing permeability of the basal 
membrane and the surrounding matrix (Tammela 2005).  
As a result of angiogenesis, a dense capillary network is formed with the ability to 
support local tissue perfusion but especially to improve the diffusion of oxygen 
from the blood to the tissue. However, these newly formed capillary tubes lack 
vascular smooth muscle cells. Any developing new network of sprouting capillaries 
that is not surrounded by mural cells is fragile and probably unable to sustain 
proper circulation. Likewise, clinical studies revealed that angiogenesis per se is 
not sufficient to fully restore the blood supply to the affected tissues (Scholz 2001; 
Henry 2003; Heil 2006).  
 
In contrast, the growth and remodelling of pre-existing collateral arteries 
bypassing an arterial occlusion much more efficiently compensate for the 
consequences of peripheral artery disease (Schaper 1971; Schaper 2001; Unthank 
2004). This adaptive remodelling process is referred to as arteriogenesis. In 
contrast to angiogenesis, arteriogenesis is not driven by the methabolic demand of 
the tissue and is initiated independently from hypoxia. The region in which 
bypassing collaterals grow is much more proximal to the hypoxic zone (Figure 2) 
(Schaper 2003), and the remodelling process is initiated by physical forces which 
appear within the collateral arteriole after a marked increase in blood flow (Heil 
2006).  
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A variety of factors have been identified that are able to therapeutically stimulate 
arteriogenesis. While some of them reached clinical testing in pilot studies, others 
had to be abandoned in the preclinical phase due to significant side effects. For 
example, granulocyte-monocyte colony-stimulating factor (GM-CSF) is having 
positive effect on arteriogenesis via circulating cells. Although the mechanisms by 
which GM-CSF stimulates arteriogenesis remain partially unclear, both 
intravascular (Buschmann 2001) as well as subcutaneous (Schneeloch 2004) 
applications of GM-CSF have been shown to effectively stimulate arteriogenesis in 
animal model experiments. In the clinical setting, however, the equipotency of 
these administration routes remains questionable. In a pilot trial in patients with 
extensive coronary artery disease, Seiler et al. demonstrated a significant positive 
effect on coronary artery flow of a single intracoronary bolus of GM-CSF followed 
by a two week subcutaneous treatment period (Seiler 2001). In the START trial, 
van Royen et al. applied a similar treatment in patients with moderate to severe 
Figure 2. Collateral growth occurs in pre-existent arterioles (taken from Schaper, 
2003). Laser Doppler image of collateral blood flow in an anesthetized mouse with 
exposed upper thigh skeletal muscles with chronic occlusion (7 days) of the left femoral 
artery. Shown are 2 preexistent arterioles that exhibit a faintly visible flow signal but a 
very strong signal on the occluded side, ie, the effect of growth after 7 days of occlusion. 
1 indicates aorta; 2, A. iliaca; 3, A. femoralis; 4, A. pudenda externa; 5, A. profunda 
femoris; 6, A. tibialis posterior; and 7, A. saphena. 
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intermittent claudication. However, in this setting of peripheral artery disease no 
beneficial effect on the primary end point walking was observed (van Royen 2005).  
Another cytokine in preclinical testing for the enhancement of collateral artery 
growth is fibroblast growth factor (FGF). Infusion of this pluripotent cytokine into 
developing collateral circulation results in a strong stimulation of arteriogenesis 
(van Royen 2002). Exogenous application of FGF2 also results in a significant 
stimulation of collateral artery growth. After recombinant FGF2 was found to be 
safe and potentially efficacious in pilot studies, Lederman et al. reported in the 
TRAFFIC study of patients with intermediate claudication a significant 
improvement in the peak walking time 90 days after the first protein infusion 
(Lederman 2002). However, while the investigators observed a trend towards 
symptomatic improvement after 90 days, this effect diminished 180 days after the 
protein infusion and no beneficial effect on myocardial perfusion or exercise 
tolerance was detected.  
Local infusion of one of the most potent pro-arteriogenic cytokines – monocyte 
chemotactic protein-1 (MCP-1) – into the collateral circulation following femoral 
artery ligation in the rabbit has been shown to significantly enhance collateral 
artery conductance compared to a control group only receiving vehicle (Ito 1997). 
Unfortunately, since the efficacy of MCP-1 infusion was shown to depend on 
monocyte chemoattraction, van Royen et al. demonstrated that local infusion of 
MCP-1 in apolipoprotein E-deficient mice results indeed in systemic monocyte 
activation, increased neointima formation and change in plague composition 
towards an unstable phenotype in pre-existing lesions (van Royen 2003). 
 
It is difficult at this time point to rate the pro-arteriogenic compounds with regard 
to their chances of future success as most substances are in early phases of 
investigation. Moreover, the eligible patient population for angiogenic/arteriogenic 
therapies needs to be better identified, as previous trials often were focused on 
patients with severe coronary artery disease, where local application of drugs is 
difficult.  The limited success of all clinical studies so far demonstrate that besides 
compound selection the issues of dosage, drug delivery and choice of valid 
endpoints remain to be solved. 
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1.2. Physical forces regulating arteriogenesis 
Morphologically, collateral arteriolar enlargement is associated with a corkscrew-
like appearance that is thought to be the consequence of a growth in length 
between two fixed points (Schaper 1971; Heil 2004). In the re-entry region they 
join up with the distal part of the occluded artery at nonphysiological angles, 
which adds to their resistance against flow.  
Based on Poiseuille´s equation  
3
8
R
QµL
P
pi
=∆  
 
(Q = volumetric flow rate; µ = viscosity; L = length; R = radius), occlusion of the 
main artery will lead to an increase in resistance and to a significant drop in 
pressure distal to the stenosis. The resulting pressure gradient enhances blood flow 
through the vascular connections like the pre-existing collateral anastamoses 
between the high-pressure region proximal to the occlusion and the low-pressure 
region distal to the occlusion (Figure 3).  
 
 
Figure 3. Scheme of the ischemic hindlimb model (taken from Heil, 2007). The 
femoral artery is ligated distally to the bifurcation of the A. profunda femoris causing a 
decrease in blood pressures distal to the side of ligation. Blood flow is redistributed 
along the blood pressure gradient, thereby recruiting pre-existing collateral 
anastomoses. 
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Not surprisingly, physical forces previously have been identified to be instrumental 
for arteriogenesis (Pipp 2004). An increased blood flow directly augments fluid 
shear stress (FSS) which is sensed by the endothelial cells of the arteriole. Hence, 
one can assume that the altered blood flow after an arterial occlusion leads to 
increased FSS which in turn is the driving force for arteriogenesis (Unthank 1996). 
However, in physical terms FSS with a range of 10-100 dyn/cm2 is a much weaker 
force acting on the arterial wall than circumferential wall strain (CWS)  
w
RP
S itmt =  
(Ptm – pressure difference, Ri – inner radius, w – vessel wall thickness), which is 10
3-
104 times higher in this case (Schaper 2003). On the other hand, even a small 
increase in the radius of the collateral arterioles leads to a decrease in FSS 
because of the cubic relationship  
pi
τ
3
4
R
µQ
=  
and hence, the FSS-related growth of the vessels ends prematurely (Schaper 2003). 
Moreover, proliferation of smooth muscle cells (SMCs) – critical for the remodelling 
of the vessel wall - is activated by an increase in pressure-related forces like CWS 
which is due to the volume-mediated distension of the vessel wall, but structurally 
weakened by matrix degradation. 
Taken together, collective evidence suggests that these two forces act together to 
alter the hemodynamics which govern arteriogenic remodelling (Scheel 1979; Pipp 
2004). This is consistent with the earlier proposed hypothesis by Price et al. that 
the maintenance of mean CWS values and the pressure-shear stress relationship 
are operative design principles for collateral arteriole development during 
physiological growth (Price 2002). 
 
1.3. Molecular mechanisms of arteriogenesis 
Presently it is not well understood how the stimulus of an increased biomechanical 
load is transmitted from the vascular cell membrane to the nucleus. The initial 
step of arteriogenesis – the elevation of shear stress - is thought to primarily affect 
the endothelial cells (ECs). Although the nature and location of the 
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mechanotransducer of shear stress are still controversial, it has been observed that 
vascular ECs lose volume control and swell due to the changes in the open 
probability of chloride channels (Ali 2002). 
Further, endothelial cells react by activating eNOS (Nishida 1992) and 
paradoxically with an increased expression of cytokines, such as MCP-1, GM-CSF 
and tumour necrosis factor-α (TNF-α) (Wahlberg 2003). Expression of selectins, 
intercellular adhesion molecules (ICAM-1 and -2) and vascular cell adhesion 
molecules (VCAM-1) is not only increased but they are also clustered in focal 
adhesion complexes (Scholz 2000). An increase in MCP-1 expression together with 
transforming growth factor-β (TGF-β) leads to the adhesion of monocytes (Hoefer 
2004; Lee 2004). And their binding  to the collateral surface is mediated by 
integrin receptors such as macrophage-1 antigen (Mac-1) and lymphocyte function-
associated antigen-1 (LFA-1). These heterodimeric molecules are counterparts of 
ICAM-1, -2 and VCAM-1 and their expression on monocytes can be up-regulated by 
growth factors (e.g. VEGF, PIGF, TGF-β) and chemokines like MCP-1 (Heil 2000; van 
Royen 2002; Pipp 2003). This pro-inflammatory differentiation of endothelial cells,  
which, however, cannot be the direct consequence of an increase in shear stress, 
finally leads to augmentation of the adhesion and recruitment of monocytes 
(Scholz 2000). 
Adhesion of monocytes that become activated during arteriogenesis is a 
prerequisite for the subsequent changes in the structure of the vessel wall 
(Schaper 1976). However, no radial growth of the arteriole can occur without a 
controlled reorganization of the original vessel architecture. After transformation 
to macrophages, monocytes produce fibronectin, proteoglycans, and proteases, 
which remodel the extracellular matrix.  These inflammatory cells also produce 
large amounts of vascular growth factors, essentially from the fibroblast growth 
factor (FGF) family, namely FGF-2 (basic FGF). One of the effects of FGF-2 binding 
to its receptor is the stimulation of endothelial and smooth muscle cell 
proliferation (Wahlberg 2003). Consequently, an active remodelling process takes 
place where the basic matrix is digested by matrix metalloproteinases (MMP-2, 
MMP-9) (Cai 2000). These proteases are up-regulated in the SMCs that 
simultaneously down-regulate the tissue inhibitor of matrix-proteases (TIMP-1).  
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Taken together, the described events are thought to increase mobility of the SMCs, 
which partially migrate into the intima, divide in situ or die by apoptosis (Scholz 
2001), resulting in radial growth of the vessel wall.  
 
1.3.1. Chemokines and arteriogenesis 
Chemokines (chemotactic cytokines) are important in leukocyte trafficking and 
influence a diverse array of normal and pathophysiologic processes including 
arteriogenesis, angiogenesis, and skeletal muscle regeneration (Charo 2004). 
Increasing evidence suggest that MCP-1–dependent recruitment of 
monocytes/macrophages is a rate limiting step in arteriogenesis and reperfusion of 
ischemic tissue.  MCP-1 (also known as chemokine ligand 2 - CCL2) belongs to the 
largest family of CC chemokines, known to attract mononuclear cells and first 
found at sites of chronic inflammation.  
Hindlimb ischemia studies using CCL2-/- mice have consistently documented a 
decreased restoration of perfusion (Voskuil 2004; Shireman 2007). Interestingly, 
several studies showed that knock-out of the MCP-1 receptor (CC chemokine 
receptor 2 - CCR2) also dramatically reduced arteriogenesis in adult animals (Heil 
2004), whereas few other studies reported the opposite - similar perfusion in CCR2 
deficient mice compared to control mice (Tang 2004). Perhaps, MCP-1 functions 
through receptors other than CCR2, and the loss of MCP-1 signalling via these 
undefined receptors may be responsible for the delayed restoration of perfusion in 
CCR2-/- mice. Moreover, CCR2-/- mice exhibit increased CCL2 in tissue compared 
with control mice in response to hindlimb ischemia (Contreras-Shannon 2007) 
which may allow binding to alternative receptors not normally activated at 
physiological levels of MCP-1 (Shireman 2007).   
Furthermore, it has been reported earlier that the infusion of MCP-1 leads to an 
increased monocyte accumulation in the walls of collateral arteries and an 
increase in collateral artery formation in the hindlimbs of MCP-1—treated animals 
compared with controls 7 days post femoral artery ligation (Ito 1997).  
Although these data suggest that chemokines such as MCP-1 are important in 
collateral artery formation, involvement in other processes occurring 
simultaneously in the adductor muscle cannot be excluded (Lee 2004). 
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1.3.2. Transcriptional regulation of MCP-1 
Multiple signalling mechanisms have been reported to be involved in MCP-1 gene 
expression in vascular cells (Shyy 1993; Roebuck 1999; Goebeler 2001) including 
but not limited to the activation of phosphatidylinositol-3-OH kinase, Akt/protein 
kinase B, phospholipase C, p60src-Ras, protein kinase C, and tyrosine kinases in 
response to a variety of stimuli like cytokines, mitogens or mechanical strain. 
These may ultimately be transmitted to the nucleus through the activation of 
mitogen-activated protein (MAP) kinases and transcription factors such as nuclear 
factor-kappa B (NF-κB) and activator protein-1 (AP-1) (Beyaert 1996; Whitmarsh 
1996; Cho 2002). These transcription factors have also been shown to contribute to 
the hemodynamic forces-induced gene expression (Wung 1997; Takemura 2004; Wu 
2007), and particularly to the cytokine-dependent induction of MCP-1 in human ECs 
(Martin 1997).  
The promoter region of the human MCP-1 gene contains putative consensus binding 
sites for a variety of transcription factors (Ueda 1994). Likewise, the triphorbol 
acetate response element (TRE), which is recognised by the AP-1 heterodimer c-
Jun and c-Fos, and/or NF-κB consensus sequence upstream of the transcription 
start site are involved in the control of MCP-1 gene expression in various cell types 
in response to diverse extracellular stimuli (Ueda 1994; Martin 1997). It has been 
suggested that the differential activation and binding of inducible transcription 
factors such as AP-1 and NF-κB to the promoter regions of chemokine genes 
provides a critical regulatory mechanism by which the chemokine can be 
selectively expressed in a cell type and stimulus-specific manner (Roebuck 1999).  
Several reports demonstrated that AP-1 is activated in vascular cells through an 
increase in static or cyclic stretch (Kumar 2003; Mitchell 2004). Accumulating 
evidence, however, suggest that reactive oxygen species (ROS) may act as second 
messengers in these cells exposed to the stretch stimulus (Satriano 1993; Lo 1996). 
Earlier studies by Wung et al. (Wung 1997) showed that MCP-1 expression is 
directly mediated by strain-induced ROS formation in vascular endothelial cells. 
For example, the antioxidant enzyme catalase, co-incubated with strained ECs, 
abolished strain-induced MCP-1 expression but had no effect on expression in static 
cells. Moreover, cyclic strain as well as H2O2 treatment induced AP-1 DNA binding 
activity, and this could be attenuated by antioxidant pretreatment of strained ECs. 
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These observations suggest that cyclic strain-induced MCP-1 expression involves 
ROS-dependent activation of the AP-1 binding sites in the MCP-1 promoter region.   
 
1.4. Aims of the study 
The induction of the expression of MCP-1 during the onset of arteriogenesis seems 
to be a key trigger in the remodelling process of collateral arterioles occurring 
after occlusion of the main artery.  Thus, the first aim of this study was to analyze 
the arteriogenic remodelling process by employing two different in vivo mouse 
models – hindlimb ischemia and ear artery ligation models and in particular to 
analyze at which time point MCP-1 expression is up-regulated in the collateral 
arterioles following artery occlusion.  
The second aim was to establish a perfusion model in situ which allowed studying 
the impact of different biomechanical forces on gene expression in situ. In this 
context, MCP-1 expression should be induced by pro-arteriogenic flow conditions 
and the cellular source of MCP-1 identified.  
The third aim was to analyse in detail how application of shear stress and cyclic 
stretch – a surrogate of circumferential wall strain – individually affects expression 
of MCP-1 in vascular both endothelial and smooth muscle cells in vitro.  
Based on these results, the final approach was aimed at characterising the 
transcriptional mechanism leading to MCP-1 expression during the onset of 
arteriogenesis.  
If successful, this study should provide new insights into the mechanism of the 
arteriogenic remodelling process and the role of MCP-1 expression during its early 
phase. The investigation would then contribute to a better understanding of the 
initiation of arteriogenesis and possibly pave a way towards an induction of this 
remodelling process as a new alternative treatment for occlusive vascular diseases.  
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2. Materials 
2.1. Antibodies 
All antibodies used for protein detection are listed in the Table 2.1. In case of 
using the DakoCytomation EnVisionTM+System-HRP (DAB) Kit, antibodies specifically 
for this kit were used according to the manufacturer’s instructions. 
Table 2.1. Antibodies used for protein detection 
Name Source 
Anti α-smooth muscle 
actin 
mouse monoclonal 
(clone 1A4) 
Dianova (Hamburg, Germany) 
Anti CD31  
rat polyclonal 
(clone MEC 13.3) 
Santa Cruz Biotechnology®, Inc. (Heidelberg, Germany) 
Anti MCP-1  
rabbit polyclonal 
AbCam® (Cambridge, UK) 
Anti F4/80  
rat polyclonal 
Dianova 
Anti-rat biotinylated DakoCytomation (Hamburg, Germany) 
 
2.2. Cell culture 
All medium and substances used for cell culture are listed in the Table 2.2. 
Table 2.2. Medium and substances for cell culture 
Medium and 
substances 
Source 
M199 InvitrogenTM (Karlsruhe, Germany) 
SMC growth media Promocell® (Karlsruhe, Germany) 
D-MEM InvitrogenTM  
Suplemental Mix Promocell® 
0.05% Trypsin/ 0.2% 
EDTA 
InvitrogenTM 
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Penicillin InvitrogenTM 
Streptomycin InvitrogenTM 
Fungizone InvitrogenTM 
FCS InvitrogenTM 
Hank’s BSS PAA (Cölbe, Germany) 
Dispase Boehringer (Mannheim, Germany) 
Gelatine Sigma-AldrichTM (Steinheim, Germany) 
Collagenase Sigma-AldrichTM 
Polyvinylpyrrolidone Sigma-AldrichTM 
 
2.3. Bacteria and plasmid vectors 
Bacterial strains and plasmid vectors used for cloning and maintenance of plasmids 
constructs are listed in Table 2.3  
Table 2.3. Bacterial E. coli strains and plasmid vectors 
A. Bacterial strain 
Strain Company Genotype 
Top 10 F 
InvitrogenTM 
(Karlsruhe, Germany) 
F´{lacIq Tn10 (TetR)} mcrA ∆(mrr-hsdRMS-
mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 
araD139 ∆(ara-leu)7697 galU galK rpsL endA1 
nupG 
B. Plasmid vector 
Vector Company Properties 
pCR®2.1-
TOPO® 
3.9 Kb 
InvitrogenTM 
pUC origin, Ampicillin & Kanamycin resistance 
genes, lacZα reporter, T7 RNA polymerase 
promoter, TA cloning site. 
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2.4. Primers 
Primers used for real-time PCR gene expression analyses are listed in Table 2.4. 
Table 2.4. Primers for real-time PCR 
Gene product 
Expected 
fragment 
length (bp) 
Annealing 
temperature 
(°C) 
Primer (forward/reverse) 
Mouse RPL32 63 60 
GGGAGCAACAAGAAAACCAA 
ATTGTGGACCAGGAACTTGC 
Mouse CD31 96 55 
GAGCCCAATCACGTTTCAGTTT 
TCCTTCCTGCTTCTTGCTAGCT 
Mouse MCP-1 64 60 
TTCCTCCACCACCATGCAG 
CCAGCCGGCAACTGTGA 
Mouse ICAM-1 49 60 
ATCTCAGGCCGCAAGGG 
CGAAAGTCCGGAGGCTCC 
 
 
2.5. Decoy oligodeoxynucleotides 
Decoy oligodeoxynucleotides used for decoy experiments are listed in table 2.5. 
Sequence specific decoys were manufactured by IBA (Göttingen, Germany). 
Table 2.5. Decoy oligodeoxynucleotides 
Name of decoy 
Sequence (forward/reverse) 
(“*” indicates phosphorothioate-bonded bases) 
AP-1 
G*T*G*CTGACTCAG*C*A*C 
G*T*G*CTGAGTCAG*C*A*C 
Mutated AP-1 
G*T*G*CTTACTTAG*C*A*C 
G*T*G*CTAAGTAAG*C*A*C 
STAT-1 
C*A*T*GTTATGCATATTCCTGTAA*G*T*G 
C*A*C*TTACAGGAATATGCATAAC*A*T*G 
Mutated STAT-1 
C*A*T*GTTATGCAGACCGTAGTAA*G*T*G 
C*A*C*TTACTACGGTCTGCATAAC*A*T*G 
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2.6. Kits 
All kits used are outlined in Table 2.6. 
Table 2.6. Kits used throughout this project 
Name Source 
A. Nucleic acid purification kits 
RNeasy® Mini Kit Qiagen (Hilden, Germany) 
QIAPrep® Spin Miniprep Kit Qiagen 
B. RT-PCR kits 
Sensiscript® Kit Qiagen (Hilden, Germany) 
Omniscript® Kit Qiagen 
QuantiTect SYBR Green® Kit Qiagen 
C. PCR cloning kits 
TOPO TA Cloning® kit InvitrogenTM (Karlsruhe, Germany) 
D. Protein detection kits 
EnVisionTM+System-HRP (DAB) 
Kit 
DakoCytomation (Hamburg, Germany) 
 
2.7. Analysis software and online tools  
Table 2.7. Software and online tools  
Program Use Reference 
A. Software 
Cell^R Imaging analysis Olympus (Hamburg, Germany) 
analySIS^D version 
5.0 
Imaging analysis Olympus Soft Imaging Systems GmbH 
InStat® version 
3.06 
Statistical analysis Graph Pad Software Inc. 
PhotoImpact XL Imaging analysis Ulead Systems, Inc. 
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Program Use Reference 
B. Online tools 
BLAST 
Finding similar 
sequences 
http://www.ncbi.nlm.nih.gov/BLAST 
Primer3 Primer design http://primer3.sourceforge.net/ 
 
2.8. Buffers and stock solutions 
2.8.1. Histological buffers and stock solutions 
Ringer solution 
154 mM NaCl 
5.6 mM KCl 
2.4 mM CaCl2 
6.0 mM NaHCO3 
 
Zinc fixative solution 
0.1 M Tris-HCl pH 7.4 
3.2 mM Ca(CH3COO)2•H2O 
22.8 mM Zn(O2CCH3)2(H2O)2 
35.9 mM ZnCl2 
 
Coloured pigment solution  
8 g HKS Gouache 318 (Schmincke, Germany) 
50 ml zinc fixative solution 
Coloured particles are dissolved by mechanical mixing and homogenized by using 
ultrasound. 
 
2.8.2. Cell biology buffers and stock solutions 
Dispase solution 
5 g lyophilised extract 
1.6 l dH2O 
 
Solution is sterile filtrated. 
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2.8.3. Molecular biology solutions 
TEN Buffer  
100 mM NaCl  
10 mM Tris pH 7.5  
1mM EDTA  
 
LB (Luria-Bertani) Medium  
To 950 ml dH
2
O add:  
Bacto-tryptone 10 g  
Bacto yeast extract 5 g  
NaCl 10 g  
 
Solutes are dissolved and pH is adjusted to 7.0 with 5 M NaOH. The volume is 
adjusted then to 1L with dH
2
O and the solution is sterilised by autoclaving for 20 
min at 15 lb/square inch.  
 
LB agar  
15 g agarose 
1l LB-medium 
 
Sterilisation as described above.  
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3. Methods 
3.1. In vivo and in situ models 
All animal studies were performed with permission of the Regional Council 
Karlsruhe and conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). 
 
3.1.1. Hindlimb ischemia model 
At least 24 weeks old male NMRI mice were anesthetized with isoflurane and the 
femoral artery was ligated just distal to the origin of the deep femoral artery using 
a 6-0 surgery silk suture The wound was closed and animals were allowed to 
recover. On day 1 or 7 after surgery, the mice were euthanized and the left 
ventricle of the heart was cannulated and perfused for 2 min at 90-100 mm Hg 
with Ringer solution containing 0.1% adenosine and 0.05% BSA (w/v) at 37°C 
followed by zinc fixative containing a colored pigment that cannot pass the 
capillary system. The hindlimbs were then dissected and processed for RNA and 
histological analyses.  
 
3.1.2. Ear artery ligation model 
For ligation of the mouse ear artery at least 24 weeks old male NMRI mice were 
anesthetized as described for the hindlimb ischemia model. The mouse ear is 
usually supplied by three, occasionally four neurovascular bundles, each consisting 
of an artery, a large vein and a nerve. Three to four consecutive orders of vessels 
with decreasing diameters originate from the major Y-shaped vascular branches 
which then drain into the capillaries (Barker 1989). First order arteries in the 
center of the ear were ligated by using 6-0 surgery silk sutures. Seven days after 
surgery, the mice were euthanized and the vasculature perfused through the left 
ventricle of the heart as described above. 
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3.1.3. Visualization of the arterial system 
Perfused mouse hindlimb and ear specimens were postfixed in zinc fixative (18 
hours) and dehydrated using a series of alcohol and isopropanol: 1 hour incubation 
in 70%, 85% and 95% ethanol each followed by 1 hour incubation in isopropanol. 
Tissues were then incubated in a mixture of benzyl alcohol and benzyl benzoate 
(1:1, v/v) having the same refractive index of the tissue for at least 18 hours. This 
procedure induces transparency of the tissue and allows detailed analysis of the 
pigment-loaded arterial system (Barker 1989) (Figure 4). The diameter of the 
collateral arterioles was measured by using the morphological analysis software 
Cell^R from Olympus at at least 3 different sites of an individual arteriole. 
 
   
 
 
 
Before perfusion After perfusion 
Selective arterial perfusion: 
Arteries filled with pigments 
Blood in arteries and veins 
V A 
Figure 4. Visualization of the arterial vasculature in the ear artery ligation model. 
The arterial system of the mouse can selectively be visualized by perfusion with 
pigmented particles that cannot pass the capillary system.  
 
- 29 -  
3.1.4. Perfusion of isolated branches of mouse mesenteric artery 
Animals were sacrificed and the ileum together with branches of superior mesenteric 
artery and vein were dissected. Second order branches of the mesenteric artery 
were excised and inserted into the perfusion chambers of the Culture Myograph 
system (DMT, Copenhagen, Denmark). The chambers were placed in an incubator at 
37°C and 5% CO2, and the branches of the arteries were continuously perfused for 6 
hours with D-MEM medium containing 15% FCS at a longitudinal pressure gradient of 
20 mm Hg with a flow of ~0.07 mL/min or at a pro-arteriogenic pressure gradient of 
50 mm Hg with a flow of ~0.17 mL/min (Figure 5).  
 
 
Figure 5. The in situ perfusion model mimics the hemodynamic situation of the collateral 
arterioles after occlusion of the main artery. Perfusion of isolated second order branches of 
the mouse mesenteric artery was performed under control conditions (∆P=20 mm Hg, flow 
~0.07 mL/min) and under pro-arteriogenic conditions (∆P=50 mm Hg, flow ~0.17 mL/min), 
resembling the increased flow in the collateral arterioles following occlusion of the femoral 
artery. 
 
Control: 
∆P 20 mm Hg 
Ligation: 
∆P 50 mm Hg 
 
Pressure gradient 
Control conditions, low flow 
70 
mmHg 
50 
mmHg 
 
Pressure gradient 
„Arteriogenic“ conditions,high flow 
70 
mmHg 
20 
mmHg 
70-80 mmHg 
50-60 mmHg 
10-20 mmHg 
70-80 mmHg 
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The functional and cellular integrity of the segments was routinely checked by their 
vasodilator response to acetylcholine (5 µM) and by immunohistochemical staining 
for the endothelial cell marker CD31 (Figure 6). 
 
 
 
3.2. Cell biology methods 
3.2.1. Culture of human umbilical vein endothelial cells (HUVECs) 
Human umbilical vein endothelial cells were isolated from freshly collected 
umbilical cords with the consent of parents. The procedure has been approved by 
the Local Ethical Committee (document number 336/2005). Umbilical veins were 
flushed with Hank’s buffer solution, filled with 10 ml dispase solution (3,1 g/l) and 
incubated for 30 min at 37°C. Veins were then flushed with 40 ml M199 medium 
which was collected in a 50-ml tube, the cell-containing medium was centrifuged 
at 1000 rpm for 5 min. The pellet was resuspended in M199 medium containing 20% 
fetal bovine serum, 50 U/ml penicillin, 50 µg/ml streptomycin and 0.25 µg/ml 
Fungizone® antimycotic, and supplemented with endothelial cell growth 
supplement. The cells were routinely cultured on plastic dishes coated with 2% 
gelatine or collagen type I coated BioFlex elastomers. Culture medium was 
changed every third day. 
 
A B M A M A 
CD31 
∆P 20 mmHg ∆P 50 mmHg 
Figure 6. Analysis of CD31 expression in isolated perfused small mouse arteries. 
Representative immunohistochemical staining (brown colour) of the endothelial cell 
marker CD31 in second order branches of the mesenteric artery verified the integrity of 
the endothelial cell monolayer after perfusion (6 hours) under control (∆P = 20 mmHg, 
low flow, A) and pro-arteriogenic (∆P = 50 mmHg, high flow, B) conditions (M – media; A 
– adventitia; scale bar=10 µm). 
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3.2.2. Culture of mouse smooth muscle cells  
Mouse smooth muscle cells were isolated from branches of the mouse mesenteric 
artery. The branches of the artery were dissected, cut into to fragments, washed 
several times with Hank’s BSS solution and transferred to a 40 mm Petri dish 
containing 250 µl of 1% collagenase solution and 1.4 ml mixture (1:1) of smooth 
muscle cell medium with D-MEM and 2,5% supplemental mix.  
Petri dishes with the fragments of mesenteric arteries were placed in an incubator 
at 37°C with 5% CO
2 
to allow hydrolysis of the extracellular matrix overnight (14-16 
hours). Isolated cells were then centrifuged for 5 min at 1000 rpm and were re-
suspended in 2 ml mixture (1:1) of smooth muscle cell medium with D-MEM and 
2,5% supplemental mix. Cells were allowed to adhere and the medium was 
changed every 4 days thereafter. After passage one the smooth muscle cells were 
cultured in D-MEM containing 15% fetal bovine serum, 50 U/ml penicillin, 50 µg/ml 
streptomycin and 0.25 µg/ml Fungizone® antimycotic. The phenotype of the cells 
was confirmed by anti-mouse α-smooth muscle actin immunofluorescent staining 
(Figure 7). 
 
 
 
 
Figure 7. Analysis of the phenotype of cultured mouse smooth muscle cells. 
Representative immunofluorescent staining for the smooth muscle cell marker α-smooth 
muscle actin (B; red fluorescence - α-SMA; blue - nuclei) in the cultured smooth muscle 
cells (A) isolated from mouse mesenteric artery. 
A B 
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3.2.3. Plating and passage of smooth muscle cells (enzymatic hydrolysis) 
Confluent cultures of smooth muscle cells were washed with serum free D-MEM 
medium, incubated with 0.05% trypsin/0.02% EDTA solution for 5 min at 37°C, re-
suspended in M199 and spun at 1000 rpm for 5 min. Thereafter, the supernatant 
was carefully removed and mSMCs were re-suspended in D-MEM with 15% FCS, 50 
U/ml penicillin, 50 µg/ml streptomycin and 0.25 µg/ml Fungizone® antimycotic. 
For the experiments described, cells of passage 3 to 4 were used throughout.  
 
3.2.4. Application of shear stress and cyclic stretch 
Confluent cultured human vascular endothelial cells were exposed to laminar shear 
stress (30 dyn/cm2) by using a cone-and-plate viscometer (Cattaruzza 2004) (Figure 
8). Shear stress stimulated and static control monolayers were cultured in the 
same medium for each experiment. One hour prior to the experiment the medium 
was changed to M199 containing 20% FCS and 6% polyvinylpyrrolidone to increase 
the viscosity of the medium. 
 
 
Application of cyclic stretch onto human vascular endothelial cells and human and 
mouse smooth muscle cells was performed by using a microprocessor controlled 
vacuum pump (FX-3000 FlexerCell Strain Unit, Flexcell, Hillsborough, NC). Both 
Figure 8. Scheme of the cone-and-plate viscometer. The essential components consist 
of a teflon cone with an angle of 0.5° rotating over a stationary base plate, which 
supports either 60 mm or 100 mm diameter polystyrene plates. The entire apparatus is 
maintained at 37°C in a humidified 5% CO2 and 95% air atmosphere.  
HUVEC 
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cell types were cultured on BioFlex collagen type I 6-well plates (Figure 9), for 
primary cultured HUVECs the plates were coated with gelatin (2 mg/ml gelatin in 
0.1 M HCl for 30 min at 37°C). Stretching was performed with 15% cyclic elongation 
at frequency of 0.5 Hz, which corresponds to the physiological maximum 
deformation in the human carotid artery (Perktold 1995).   
 
 
 
3.2.5. Stimulation of cultured cells with Idebenone or glucose oxidase  
Cells were stimulated with glucose oxidase reagent (final concentration 12 mU/ml, 
Sigma-Aldrich) or with Idebenone reagent (final concentration 3 µM, Takeda 
Pharma AG). For one well of a 6-well plate 2 µl of glucose oxidase in dH2O or 
Idebenone in DMSO was added to a medium volume of 2 ml. Cells were kept at 
37°C and 5% CO2 at static conditions or exposed to cyclic stretch for 6 hours. 
 
3.3. Molecular biology methods 
3.3.1. Isolation of total RNA 
Total RNA was isolated from cultured cells, individually excised collateral 
arterioles and isolated branches of mouse mesenteric arteries using the RNeasy® 
kit according to the manufacturer’s instructions. An aliquot of 13 µl of RNA was 
used to make single-stranded (ss) cDNA for RT-PCR reactions (3.3.2.).  
 
Figure 9. Scheme of the BioFlex collagen type I elastomer. BioFlex culture 6-well plates 
are fixed in the BioFlex baseplate and maintained at 37°C in a humidified 5% CO2, 95% air 
atmosphere. The computer-regulated bioreactor applies cyclic tensile stain to the cells by 
using regulated vacuum pressure to deform the flexible-bottomed culture plates 
producing up to 30% substrate elongation. 
.   
HUVEC / SMC 
cyclic stretch 
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3.3.2. RT-PCR 
Conventional RT-PCR was performed by using Oligo(dT)15 primers (Promega, 
Mannheim, Germany) and the Sensiscript® kit for material from the isolated mouse 
arteries or the Omniscript® kit for material from the cultured cells and the 
dissected mouse arterioles according to the manufacturer’s instructions. 
 
3.3.3. Measurement of RNA/cDNA concentration 
Measurement of RNA and cDNA concentrations was performed by using the 
NanoDrop® ND-1000 spectrophotometer. For quantitative real-time PCR analysis 80 
pg - 1 ng of cDNA was used (3.3.4.).  
 
3.3.4. Quantitative real-time PCR 
Real-time PCR was carried out in a LightCycler instrument (Roche Diagnostics, 
Penzberg, Germany) by using the QuantiTect SYBR Green® kit according to the 
manufacturer’s instructions. Standard cDNA probes for quantitative analysis were 
generated by using the TOPO TA Cloning® kit (3.3.5.1.). As an internal standard 
the ribosomal protein L32 (RPL32) or the endothelial cell marker platelet 
endothelial cell adhesion molecule-1 (PECAM-1 or CD31) were chosen. 
 
3.3.5. TOPO cloning 
Amplified DNA fragments of the desired molecules were cloned into the pCR® 
TOPO 2.1 vector (3.9 Kb) using the TOPO TA Cloning® Kit according to the 
manufacturer’s instructions. Plasmids containing the inserts were amplified further 
(3.3.5.1.). 
 
3.3.5.1. Transformation of competent bacteria 
pCR® TOPO vector with insert was mixed with 20 µl of Top10FTM competent cells in 
a 1.5 ml Eppendorf tube and incubated on ice for 30 min. Thereafter, cells were 
submitted to the heat shock at 42°C for 40 s, and placed back on ice. Two hundred 
and fifty µl of SOC medium was added to the cells and the suspension incubated at 
37°C for 1 h with shaking at 300 rpm. Sterile LB-agar medium with 20 µg/ml of 
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ampicillin in Petri dishes was pre-warmed to 37°C and 25 µl and/or 75 µl of 
transformed competent cells were plated onto the dishes. Plates were then 
incubated at 37°C overnight to allow bacterial colonies to grow. 
 
3.3.5.2. Plasmid mini-cultures and plasmid purification 
Transformed colonies of Top10FTM competent cells were picked by using a sterile 
pipette tip and added to 3 ml of LB Broth (with appropriate antibiotic) in 15 ml 
falcon tubes. Caps of the falcon tubes were perforated to allow air to circulate 
through the tube. These cultures were then incubated at 37°C with shaking 
overnight.  
Plasmids grown in minicultures were purified using the QIAPrep® Spin Miniprep Kit 
according to the manufacturer’s instructions. 
 
3.3.6. Decoy oligodeoxynucleotide technique 
3.3.6.1. Hybridization of decoy oligodeoxynucleotides 
Equal volumes of single-stranded phosphorothioate-bonded decoy 
oligodeoxynucleotides (dODNs) were mixed and melted at 95°C for 5 min in a 
water bath. The dODNs were then allowed to cool down to approximately 30°C in 
the water bath. The efficiency of the hybridization reaction was verified with 2.5% 
agarose gel electrophoresis in comparison with the single stranded 
oligodeoxynucletides and usually found to exceed 95% (Figure 10). 
 
 
Figure 10. Hybridization of dODNs. Exemplary agarose gel depicting single-stranded 
(ss) vs. hybridised double-stranded (ds) oligodeoxynucleotide.  
 
AP-1 dODN 
ss        ds ODN 
STAT-1 dODN 
ss        ds ODN 
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3.3.6.2. Administration of the decoy oligodeoxynucleotides  
The transcription factor decoys are molecules that mimic the binding sites for 
transcription factor proteins, and compete with promoter regions to absorb this 
binding activity in the cell nucleus (Figure 11). 
Cultured mSMCs and isolated mouse arteries were transfected with naked ODNs (10 
µmol/L), i.e. without using any cationic lipid or liposomal complex for 4 hours at 
37°C.  
For local application in vivo, hybridized ODNs were mixed with Unguentum 
emulsificans to yield a final concentration of 0.25% (w/v) and 20 mg of this mixture 
was homogeneously spread across the surface of the mouse ear one day before, 
directly after occlusion of an artery, and then every second day thereafter until 
euthanization of the animals on day 7. 
 
 
 
 
 
 
Figure 11. Transcription factor-decoy strategy (taken from Mann, 2005). 
Transcription factor decoys mimic the sequence specific binding sites for transcription 
factor proteins that are found in the promoter regions of target genes. Delivery of the 
decoy to the cell leads to binding of the transcription factor and prevention of 
transactivation (or suppression) of the target gene. 
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3.4. Protein biochemistry methods 
3.4.1. Immunohistological analysis 
Immunohistochemical and immunofluorescence staining for MCP-1, CD31 or F4/80 
was performed on 5-µm paraffin or frozen sections by using the polyclonal rabbit 
anti-mouse MCP-1 and rat anti-mouse CD31 antibody in combination with an 
enhanced detection method (Envision™, DAKO, Hamburg, Germany) and 3, 3 -
diaminobenzidine (DAB) as a substrate; or the polyclonal rat anti-mouse F4/80 
antibody with biotinylated rabbit anti-rat antibody and Streptavidin-RPE (DAKO) 
according to the manufacturers instructions. Nuclei were visualized by Mayer´s 
hemalaum counter stain or Hoechst dye 33258. MCP-1 staining intensity was 
determined by using the Cell^R software analyzing at least two different sections 
per experimental group and animal. Exposure times during digital imaging were 
kept constant. 
 
3.4.2. Dihydroethidium staining 
Detection of reactive oxygen species (ROS) by using dehydroethidium (DHE), which 
is rapidly oxidized by ROS into its derivative ethidium bromide, was performed 
with cells cultured on elastomers or with freshly prepared 5-7 µm frozen sections. 
Dihydroethidium was added onto the sections or into the cell culture medium at a 
final concentration of 5 µM in PBS. After 30 min of incubation at 37°C, sections or 
cells were washed with PBS and covered with coverslips. Fluorescence intensity 
was determined as described above.  
 
3.4.3. Bandeiraea lectin staining 
To visualize blood vessels in whole mount preparations of mouse tissues, 200 µl of 
biotinylated Bandeiraea (BS-I) lectin labelled with FITC was injected intravenously 
into the tail vein of anesthetized mice and allowed to circulate for 3-5 min. 
Thereafter, animals were sacrificed and perfused through the left ventricle of the 
heart with Ringer solution followed by 1% paraformaldehyde (PFA) solution. 
Arterioles from mouse hindlimbs were dissected from adductor, medial large and 
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gracilis muscles and the fluorescence was detected by confocal microscopy as 
described above.  
 
3.4.4. ELISA 
The concentration of MCP-1 protein in supernatants from mSMCs and HUVECs was 
determined by ELISA kits from R&D Systems® according to the manufacturer’s 
instructions. The human MCP-1 immunoassay was carried out with 1:10 diluted 
media samples and the mouse MCP-1 immunoassay with the media samples diluted 
1:5. For both assays, the values obtained under control conditions were set to 
100%.  
 
3.5. Statistical analysis 
All results are expressed as means±SEM. Differences between experimental groups 
were analyzed by unpaired Student’s t-test using the Instat™ version 3.06 statistics 
software package (Graph Pad Software, San Diego, CA, USA). P-values < 0.05 were 
considered statistically significant. 
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4. Results 
4.1. Hind limb ischemia model 
4.1.1. Arteriogenic remodelling is characterized by an increase in diameter of 
collateral arterioles after femoral artery ligation 
In order to analyze the arteriogenic remodelling process of collateral arterioles in 
mouse hindlimbs, the femoral artery was ligated just distal to the origin of the 
deep femoral artery. The growing collaterals in the hindlimb follow a constant 
course on the surface of the adductor muscles facilitating their identification in 
transparent tissue and histological preparations (Scholz 2002; Deindl 2003). On day 
7 after femoral artery ligation the remodelled collaterals were easily identified by 
their corkscrew-like morphology (Figures 12A-B, arrows) and increase in diameter 
(Figure 12C).   
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Figure 12. Analysis of collateral arteriolar remodelling in the mouse hindlimb. 
Images of particle-perfused transparent mouse hindlimbs (A, sham operated; B, ligated, 
scale bar=1 mm). Arteriogenic remodelling of collateral arterioles is indicated by their 
tortuous morphology (arrows) and increased diameter (C, **P<0.01 vs. sham, n=5). 
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4.1.2. MCP-1 is one of the first molecules up-regulated during the onset of 
arteriogenesis 
The remodelling process of collateral arterioles after femoral artery ligation in 
mouse hindlimbs was accompanied by an increase in the expression of MCP-1 which 
was observed by using real-time PCR analysis already at 24 hours as well as 7 days 
post ligation (Figure 13A). Due to the defined and thus predictable anatomy of 
collateral arterioles in the mouse hindlimb, expression of MCP-1 in these vessels 
could also be analyzed 24 hours after ligation of the femoral artery even without 
establishing their tortuous morphology.  Similarly, the expression of ICAM-1, 
another well known gene product the up-regulation of which is associated with 
arteriogenesis (Hoefer 2004; Hur 2007), was also up-regulated 7 days post 
occlusion in the remodelling collateral arterioles (Figure 13B). ICAM-1 is expressed 
mainly in endothelial cells, therefore analysis of its mRNA abundance was 
normalized by using the endothelial cell marker CD31. 
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Figure 13. Expression of MCP-1 and ICAM-1 in collateral arterioles undergoing 
arteriogenesis in mouse hindlimbs after femoral artery ligation. Quantitative 
real-time PCR analyses of MCP-1 (A, *P<0.05 vs. sham, ##P<0.01 vs. sham, n=5) and 
ICAM-1 (B, **P<0.01 vs. sham, n=5) expression in individual arteriogenic arterioles 
after femoral artery occlusion in the hindlimb ischemia model in mice (MCP-1/RPL 
and ICAM-1/CD31 ratio under control conditions was set to 100%).  
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4.2. Ear artery ligation model 
4.2.1. Arteriogenic remodelling in the mouse ear is characterized by an 
increase in number and diameter of corkscrew-like arterioles after artery 
occlusion  
In order to analyse the arteriogenic remodelling process more closely, a mouse ear 
artery ligation model was employed. Similar to the hindlimb ischemia model, 
ligation of one first order mouse ear artery resulted in an increase in diameter 
(Figure 14C) as well as the number (Figure 14D) of corkscrew-like collateral 
arterioles (Figures 14B, arrows).  
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Figure 14. Analysis of collateral arteriolar remodelling in the mouse ear. Images of 
particle-perfused transparent mouse ears (A, sham operated; B, ligated, scale bar: 0.5 
mm) 7 days after arterial occlusion. Arteriogenic remodelling of collateral arterioles is 
indicated by their tortuous morphology (arrows), increased diameter (C, *P<0.05 vs. 
sham, n=5) and number (D, *P<0.05 vs. sham, n=5). 
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4.2.2. Adaptive remodelling of collateral arterioles after ear artery ligation is 
accompanied by an increased expression of MCP-1 and ICAM-1 
The expression of MCP-1 and ICAM-1 in single isolated collateral arterioles from the 
mouse ear was analyzed as well by using real-time PCR analysis. Likewise, 
expression of MCP-1 (Figure 15A) and ICAM-1 (Figure 15B) in corkscrew-like 
collateral arterioles from the mouse ear 7 days post artery occlusion was 
significantly increased compared to collaterals isolated from sham-operated ears.   
  
 
 
 
 
4.3. Perfusion model of isolated branches of the mouse mesenteric 
artery  
4.3.1. Pro-arteriogenic perfusion conditions up-regulate MCP-1 expression in 
vascular smooth muscle cells  
To mimic the changes in arteriolar perfusion which occur after occlusion of the 
femoral artery, an in situ perfusion model was established. This model is mainly 
based on the fact that mean arterial pressure distal to the site of occlusion drops 
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Figure 15. Expression of MCP-1 and ICAM-1 in arteriogenic collateral arterioles 
isolated from the mouse ear.  MCP-1 (A, *P<0.05 vs. sham, n=5) and ICAM-1 (B, *P<0.05 
vs. sham, n=5) expression in isolated control and arteriogenic arterioles was determined 
by real-time PCR analyses in the mouse ears (MCP-1/RPL32 and ICAM-1/CD31 ratios 
under control conditions were set to 100%).  
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thereby increasing the pressure difference between both ends of the collateral 
arterioles (Helisch 2003; Heil 2004). As a result of the experimentally set pressure 
gradient (50 mm Hg vs. 20 mm Hg), flow increased proportionally to the difference 
in pressure from ~0.07 ml/min to ~0.17 ml/min in the isolated perfused second 
order branches of the mouse mesenteric artery. Immunohistochemical analyses 
revealed an increased abundance of MCP-1 in the media of these segments upon 
perfusion under pro-arteriogenic conditions for 6 hours (compare Figures 16A and 
B).  
 
 
 
To localize the source of MCP-1 expression in the perfused branches of the 
mesenteric artery, the endothelial cell layer was mechanically removed by 
denuding the vessels just after termination of perfusion. Immunohistochemical 
analyses confirmed the increase in MCP-1 abundance in the media upon perfusion 
under pro-arteriogenic conditions (compare Figures 17A and B).  
 
A B M A M A 
MCP-1 
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Figure 16. Analysis of the expression of MCP-1 in isolated perfused small mouse 
arteries. Immunohistochemical staining of MCP-1 (brown colour) revealed an increased 
abundance of the cytokine in the media upon exposure to an increased pressure 
gradient (B; M – media; A – adventitia; scale bar=10 µm). 
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Moreover, real-time PCR analyses of the perfused arteries confirmed that 
mechanical removal of the endothelial cell monolayer did not affect the relative 
change in MCP-1 mRNA abundance under pro-arteriogenic flow conditions (Figure 
18).  
 
 
 
 
Figure 17. Analysis of the expression of MCP-1 in isolated perfused small mouse 
arteries after removal of the EC monolayer. Immunohistochemical staining of MCP-1 
(brown colour) revealed an increased abundance of the cytokine in the media after 
perfusion under pro-arteriogenic conditions (B; M – media; A – adventitia; scale bar=10 
µm). 
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Figure 18. Analysis of MCP-1 mRNA abundance in isolated perfused branches of the 
mouse mesenteric artery. Compared to the perfused arteries with the intact EC 
monolayer, its mechanical removal after perfusion did not alter the increase in the 
MCP-1 mRNA after exposure to pro-arteriogenic perfusion conditions as evidenced by 
real-time PCR. (*P<0.05 vs. control, i.e. ∆P=20 mm Hg, #P<0.05 vs. control, n=6; MCP-
1/RPL32 ratio under control conditions was set to 100%). 
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4.4. Effects of shear stress and cyclic stretch application in vitro 
As an increase in flow with the resulting distension of the vessel wall affects both 
shear stress and circumferential wall strain, the impact of these two 
biomechanical forces on MCP-1 expression in cultured cells was analyzed 
individually. 
 
4.4.1. Cyclic stretch rather than shear stress up-regulates MCP-1 expression in 
cultured vascular cells 
Cultured HUVECs were exposed to fluid shear stress (30 dyn/cm2) for 6 hours and 
analyzed by real-time PCR and ELISA for MCP-1 expression. An increase in shear 
stress had no effect on MCP-1 mRNA (Figure 19A) and protein (Figure 19B) in the 
cultured HUVECs.  
 
 
This effect was also confirmed in endothelial cells isolated from the mouse lung 
microvasculature (Figure 20A) and in the mouse EC cell line bEnd.3 isolated from 
the cerebral cortex (Figure 20B and 21). 
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Figure 19. Analysis of MCP-1 expression in cultured endothelial cells in response to 
shear stress. MCP-1 mRNA levels (A, real-time PCR analysis) and MCP-1 protein levels in 
supernatants of HUVECs (B, ELISA) were not significantly altered following exposure to 
shear stress (30 dyn/cm2) for 6 hours (n=3; MCP-1 expression/release under static 
conditions was set to 100%). 
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As a surrogate parameter for an increase in circumferential wall strain, cyclic 
stretch was applied to the cultured HUVECs and mSMCs for 6 hours (15% elongation 
at 0.5 Hz). In contrast to the shear stress experiments, quantitative real-time PCR 
analyses revealed an increased expression of MCP-1 in both cell types on the mRNA 
level (Figure 22A). MCP-1 protein abundance determined by ELISA was also 
significantly increased in both types of cells upon exposure to cyclic stretch as 
compared to the static controls (Figure 22B).  
 
Figure 21. Exemplary analysis of MCP-1 expression in cultured endothelial cells in 
response to shear stress. MCP-1 protein abundance (ELISA) in supernatants of the in 
mouse EC cell line bEnd.3 was not significantly changed after exposure to shear stress (30 
dyn/cm2) for 6 hours (n=1, the level of MCP-1 release under control conditions was set to 
100%). 
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Figure 20. Exemplary analysis of MCP-1 expression in cultured mouse endothelial cells in 
response to shear stress. MCP-1 mRNA levels (real-time PCR) in endothelial cells isolated 
from mouse lung microvasculature (A) and in the mouse EC cell line bEnd.3 (B) were not 
significantly changed after exposure to shear stress (30 dyn/cm2) for 6 hours (n=1, the level 
of MCP-1/RPL32 under control conditions was set to 100%). 
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These results were confirmed with cultured human smooth muscle cells where 
application of cyclic stretch rapidly induced MCP-1 expression on the protein level 
(Figure 23). 
 
 
 
Figure 23. Analysis of MCP-1 expression in cultured human smooth muscle cells in 
response to cyclic stretch. Exposure to cyclic stretch (15% elongation at 0.5 Hz) of 
SMC isolated from human thymus veins for 6 hours increased MCP-1 protein expression 
(ELISA; *P<0.05 vs. static control, n=6). The level of MCP-1 release under control 
conditions was set to 100%. 
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Figure 22. Analysis of MCP-1 expression in cultured endothelial and smooth muscle 
cells in response to cyclic stretch. Exposure to cyclic stretch (15% elongation at 0.5 Hz) 
of both HUVEC and mSMC for 6 hours similarly increased the abundance of MCP-1 mRNA 
(A, real-time PCR; *P<0.05, #P<0.05 vs. static control, n=3) and protein (B, ELISA; 
*P<0.05, #P<0.05 vs. static control, n=3). The level of MCP-1 expression/release under 
control conditions was set to 100%. 
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4.5. The impact of AP-1 activation on the regulation of MCP-1 
expression 
Among several mechanosensitive transcription factors, AP-1 has repeatedly been 
shown to contribute to stretch-induced gene expression in vascular cells and this 
also seems to apply to the regulation of several pro-inflammatory gene products 
(Wung 1997; Park 1999; Kumar 2003). Therefore, the role of AP-1 in stretch-
induced MCP-1 expression was analyzed.   
 
4.5.1. Expression of MCP-1 induced by pro-arteriogenic perfusion conditions is 
dependent on the activation of AP-1 
In order to analyze whether activation AP-1 is necessary for MCP-1 expression, the 
decoy oligodeoxynucleotides technique was employed first in the isolated branches 
of the mouse mesenteric artery. The gene expression studies showed that pre-
treatment with an appropriate AP-1 dODN completely abrogated the increase in 
MCP-1 expression in arteries exposed to pro-arteriogenic perfusion conditions 
(Figure 24).  
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Figure 24. Analysis of the role of AP-1 in the mechanosensitive expression of MCP-1. 
Pre-treatment of arterial segments with the AP-1 dODN (10 µmol/L) for 4 hours abolished 
the increase in MCP-1 expression under pro-arteriogenic perfusion conditions (∆P = 50 
mmHg) whereas treatment with mutant control ODN had no effect (real-time PCR 
analysis; *P<0.05 vs. control, i.e. ∆P=20 mm Hg, n=6; MCP-1 mRNA under control 
conditions was set to 100%).  
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To verify the specificity of the AP-1 dODN, a mutant control ODN was administered 
in parallel to the isolated branches of the mouse mesenteric artery, but did not 
affect MCP-1 expression induced by pro-arteriogenic perfusion conditions (Figure 
24).   
 
4.5.2. Activation of AP-1 is critical for stretch-induced MCP-1 expression in 
vitro 
Cultured mouse smooth muscle cells were pre-treated with the AP-1 dODN and 
exposed to cyclic stretch for 6 hours (15% elongation at 0.5 Hz). Gene expression 
analysis by real-time PCR showed that inhibition of AP-1 activity abolished stretch-
induced MCP-1 expression on the mRNA level (Figure 25A). ELISA further confirmed 
that stretch-induced expression of MCP-1 protein was completely abrogated as well 
(Figure 25B). Treatment with the control ODN, on the other hand, had no effect on 
the expression of MCP-1 mRNA or protein in the cultured mSMCs (Figure 25).  
 
 
 
Figure 25. Analysis of MCP-1 expression in stretch-stimulated cultured mouse smooth 
muscle cells treated with the AP-1 dODN. Treatment with the AP-1 dODN but not the 
mutant control ODN inhibited stretch-induced expression of both MCP-1 mRNA (A, real-time 
PCR; *P<0.05, #P<0.05 vs. static control, n=3) and protein (B, ELISA; *P<0.05, #P<0.05 vs. 
static control, n=3). The level of MCP-1 expression/abundance under control conditions was 
set to 100%. 
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4.6. Analysis of ROS formation in cells exposed to cyclic stretch 
and in the perfused arteries 
4.6.1. Cyclic stretch increases production of ROS in cultured smooth muscle 
cells  
The transcription factor AP-1 has been shown to be activated by increased 
formation of reactive oxygen species (ROS). Therefore, formation of ROS in the 
cultured smooth muscle cells upon exposure to cyclic stretch was analyzed. 
Incubation of the cultured cells with dihydroethidium revealed a marked increase 
in ROS formation 6 hours after exposure to cyclic stretch which was abolished in 
the presence of the ROS scavenger Idebenone (Figure 26) verifying the specificity 
of the dehydroethidium detection method.  
 
 
static control cyclic stretch (6h) 
Idebenone (3 µM) 
control 
A B 
C D 
Figure 26. Formation of reactive oxygen species (ROS) in stretched mSMCs. 
Detection of ROS by dihydroethidium in stretch-stimulated mSMCs in the absence (A, 
static control; B, cyclic stretch: 15% elongation at 0.5 Hz for 6 hours) and in the 
presence of the ROS scavenger Idebenone (3 µM; C, control; D, cyclic stretch; scale 
bar=50 µm). 
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In order to delineate a role for ROS in the regulation of MCP-1 expression, cultured 
mouse smooth muscle cells were exposed to cyclic stretch in the presence of 
Idebenone (3 µM) for 6 hours. Quantitative real-time PCR analyses revealed that in 
contrast to the previous series of experiments there was no stretch-induced 
increase in MCP-1 expression both on the mRNA (Figure 27A) and protein level 
(Figure 27B) in the presence of Idebenone.  
 
 
 
 
4.6.2. Formation of ROS is necessary for MCP-1 expression induced by pro-
arteriogenic flow conditions in situ 
Similarly, an enhanced ROS formation was detected in the isolated perfused 
branches of the mouse mesenteric artery. Immediately after perfusion the vessel 
segments were frozen in liquid nitrogen and 5 µm sections were incubated with 
dihydroethidium. Analysis of the fluorescence intensity revealed that perfusion 
under pro-arteriogenic flow conditions for 6 hours induced an increase in ROS 
formation mainly in the media of the vessels (Figure 28). 
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Figure 27. Analysis of MCP-1 expression in cultured mouse smooth muscle cells in 
response to cyclic stretch in the presence of Idebenone. Exposure to cyclic stretch 
(15% elongation at 0.5 Hz) for 6 hours in the presence of Idebenone (3 µM) failed to 
raise MCP-1 mRNA (A, real-time PCR; n=3) or protein (B, ELISA; n=3) levels. The level of 
MCP-1 expression/release under control conditions was set to 100%. 
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Similarly, the effect of Idebenone was investigated in the perfused branches of the 
mouse mesenteric artery where it inhibited MCP-1 mRNA expression induced by 
pro-arteriogenic flow conditions (Figure 29). 
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Figure 29. Analysis of MCP-1 expression in isolated perfused branches of the mouse 
mesenteric artery in the presence of Idebenone. In the presence of Idebenone (3 µM) 
there was no increase in MCP-1 mRNA abundance, as analyzed by real-time PCR, upon 
perfusion under pro-arteriogenic conditions (n=6, MCP-1/RPL32 ratio under control 
conditions was set to 100%).  
∆P 20 mm Hg ∆P 50 mm Hg 
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Figure 28. Analysis of ROS formation in isolated perfused mouse arteries. Detection 
of ROS by dihydroethidium (A, perfusion under control conditions; B, perfusion under 
pro-arteriogenic conditions; scale bar=100 µm) revealed that pro-arteriogenic flow 
conditions enhance ROS formation in the isolated arterial segments. 
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4.6.3. An increased ROS formation is associated with collateral arterioles 
undergoing arteriogenesis  
Furthermore, ROS formation in the collateral arterioles of the mouse hindlimbs 
was analyzed after femoral artery occlusion. Shortly before animals were 
sacrificed DHE solution in PBS and BS I Lectin labeled with FITC (to identify the 
vessels in the muscle of the hindlimb) were injected into the mouse tail vein. By 
using confocal microscopy an increased ROS formation was detected associated 
with the collateral arterioles in the mouse hindlimbs 3 days after occlusion of the 
femoral artery compared to arterioles from sham-operated animals (Figure 30).   
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Figure 30. Formation of ROS in collateral arterioles after ligation of the femoral 
artery (mouse hindlimb ischemia model). Detection of ROS by dehydroethidium (red 
fluorescence), combined with BS I lectin-FITC labeling of the vessel wall (green 
fluorescence) in collateral arterioles of the mouse hindlimb 3 days after ligation of the 
femoral artery (A-C, sham; D-F, ligation; scale bar=50 µm).  
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4.6.4. Expression of MCP-1 can be induced by an increase in exogenous ROS 
formation in vitro 
Cultured smooth muscle cells were stimulated with glucose oxidase to induce 
exogenous formation of hydrogen peroxidase and analyze its effect on MCP-1 
expression in these cells. Quantitative real-time PCR analysis demonstrated an 
increased expression of MCP-1 in the mSMCs after exposure to glucose oxidase 
(Figure 31A). Unexpectedly, MCP-1 protein abundance did not change significantly 
in the presence of glucose oxidase (Figure 31B). 
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Figure 31. Expression of MCP-1 in cultured mouse smooth muscle cells stimulated 
with glucose oxidase. Exposure to glucose oxidase (12 mU/ml) for 6 hours at 37°C 
resulted in increased MCP-1 expression on the mRNA level (A, real-time PCR analysis, 
n=3, *P<0.05) while that on the protein level did not reach statistical significance (B, 
ELISA, n=3). The level of MCP-1 expression/release under control conditions was set to 
100%. 
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4.7. Activation of AP-1 is crucial for MCP-1 expression and 
monocyte recruitment during arteriogenesis 
Since the aforementioned data had identified AP-1 as a pivotal factor in stretch-
induced MCP-1 expression in vascular SMCs in vitro and in situ, the role of AP-1 
during arteriogenesis in vivo was further analyzed. To this end, the mouse ears 
were treated with a topical formulation of the AP-1 dODN or the corresponding 
control ODN during the induction and early manifestation phase of the remodelling 
process. Topical administration of the fluorescent dye-labelled dODN as an 
ointment resulted in an excellent penetration of the nucleic acid through the skin 
into the wall of the ear blood vessels within 24 hours after the first application 
where it was still detectable after 48 hours (Figure 32). Thus, the ointments 
containing the AP-1 dODN and the corresponding control ODN were topically 
administered to the mouse ear the day before the ligation was made, on the day of 
the ligation and every 48 hours following the ligation of the ear artery.    
 
Seven days after occlusion of the main supplying artery in one ear the animals 
were sacrificed and the ears harvested for further analyses. Morphological analysis 
by using coloured particle-perfusion showed that topical application of the AP-1 
dODN completely abrogates the arteriogenic remodelling process when compared 
to treatment with the mutant control ODN (Figures 33A-C).   
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Figure 32. Monitoring of the penetration of the AP-1 dODN through the skin of the 
mouse ear. Fluorescence dye ATTO*565-labelled AP-1 dODN (red fluorescence) was 
homogeneously administered once to the surface of the ear and monitored 1, 2 and 7 
days later by way of confocal fluorescence microscopy (left panel, endothelial cells in 
the ear blood vessels were labelled by perfusion with BS I lectin-FITC, green 
fluorescence). Labelled AP-1 dODN was detected adjacent to ear blood vessels (right 
panel, arrow) and in endothelial cells (right panel, inserts). 
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Closer analysis revealed that both the enlargement (Figure 34A) and increase in 
the number of collateral arterioles with corkscrew-like morphology (Figure 34B) 
was virtually blunted upon treatment with the AP-1 dODN, while treatment with 
the mutant control ODN had no such effect. In addition, real-time PCR analyses 
confirmed that there was no arteriogenesis-associated increase in MCP-1 
expression in the collateral arterioles of AP-1 dODN-treated animals (Figure 34C). 
Treatment with the mutant control ODN, on the other hand, did not affect the 
increase in MCP-1 mRNA level in the remodelling collateral arterioles.  
 
A 
B 
Figure 33. Visualization of the 
effects of AP-1 dODN blocking AP-1 
activity on the arteriogenic 
remodelling process in the mouse 
ear 7 days after occlusion of the 
main artery (A, arrows). Topical 
treatment with the AP-1 dODN (C) but 
not the mutant control ODN (B, for 
details of the treatment regimen 
refer to the Methods section) 
inhibited collateral arteriolar 
remodeling (B, C, arrows; scale bar: 1 
mm) as indicated by the reduced 
number of corkscrew-like arterioles.  
 
C 
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Since MCP-1 is a powerful chemoattractant for circulating monocytes (Ernst 1994), 
the effect of the AP-1 dODN treatment on the recruitment of monocytes to the 
arteriogenic vessel wall was analyzed. Following treatment with the AP-1 dODN but 
not the mutant control ODN there was a marked decline in the number of F4/80-
positive macrophages surrounding the arteriolar vessel wall (Figure 35). 
 
 
Figure 34. Analysis of the effects of AP-1 inhibition in the mouse ear artery ligation 
model. Diameter and number of corkscrew-like blood vessels is decreased by treatment 
with the dODN 7 days post ear artery occlusion and accompanied by a decrease in MCP-1 
expression as evidenced by real-time PCR analyses (A-C, *P<0.05, ***P<0.001 vs. non-
treated control mouse ears, n=5). 
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4.8. Inhibition of STAT-1 activity does not affect arteriogenic 
remodelling of collateral arterioles 
In order to delineate effects associated with the activity of AP-1 from that of other 
pro-inflammatory transcription factors on the arteriogenic remodelling process, 
decoy oligonucleotides specific for neutralizing signal transducer and activator of 
transcription-1 (STAT-1) were administration in the same manner to the skin of 
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Figure 35. Effect of the topical AP-1 dODN treatment on arteriogenesis-associated 
monocyte recruitment. Representative immunofluorescence images showing F4/80-
positive macrophages (red fluorescence, arrows) surrounding collateral arterioles (nuclei, 
blue fluorescence; dotted circle: arteriole filled with particles showing intense red 
autofluorescence; scale bar: 25 µm) 7 days post occlusion of the main artery in control 
(A), mutant control ODN-treated (B) and AP-1 dODN-treated (C) mouse ears. The number 
of F4/80-positive macrophages surrounding arteriogenic collateral arterioles is 
significantly reduced by treatment with the AP-1 dODN (D, **P<0.01 vs. untreated 
arteriogenesis control, n=5). 
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mouse ear. On day 7 after ligation of an ear artery the mice were sacrificed and 
ears dissected as described above.  
 
 
 
Morphological analysis with coloured particle-perfusion showed that blockade of 
STAT-1 activity did not affect the arteriogenic remodelling process in the mouse 
ear (Figure 36). This lack of effect was further detailed by quantification of the 
number and diameter of the corkscrew-like collateral arterioles (Figure 37).  
 
Figure 36. Visualization of the effects of 
STAT-1 inhibition on arteriogenic 
remodelling of the arterioles in the mouse 
ear 7 days after occlusion of the main 
artery (A, arrows). Topical treatment with 
the STAT-1 dODN (C) as well as the mutant 
control ODN (B, for details of the treatment 
regimen refer to the Methods section) did 
not affect collateral arteriolar remodelling 
(arrows; scale bar: 1 mm).  
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Figure 37. Analysis of the effects of STAT-1 inhibition in the mouse ear artery 
ligation model. Diameter (A, n=3) and number (B, n=3) of corkscrew-like collateral 
arterioles is not affected by STAT-1 dODN treatment 7 days post ear artery occlusion 
compared to ears treated with the mutant control ODN. 
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5. Discussion 
Occlusive vascular diseases continue to be the most common cause of death in the 
Western world and hence constitute a high unmet medical need. In the 
Cardiovascular Health Study, peripheral artery disease was found in 13.9% of 2214 
men aged ≥ 65 years and in 11.4% of 2870 women aged ≥ 65 years without known 
cardiovascular disease (Newman 1993). In Germany, prevalence was 9.2% of 6880 
males over 65 years of age in primary care (Diehm 2004). With the progress in the 
field of percutaneous intervention and vascular surgery, development of 
atherosclerotic vascular disease has become treatable in a growing number of 
patients. However, in a significant amount of cases the disease can not be treated 
effectively. Patients suffering from peripheral artery disease have a large number 
of co-morbidities including coronary heart disease (angina, myocardial infarction) 
and cerebrovascular disease (stroke) increasing the risk particularly of surgical 
therapies (Nikol 2007).   
Alternative approaches to restore blood flow to the ischemic tissue are needed for 
those patients with untreatable lesions or contraindications to surgical 
interventions. As a consequence, several strategies are currently tested to 
stimulate collateral artery growth and the formation of natural bypasses 
(arteriogenesis). Therapeutic stimulation of this protective mechanism, which is 
far more efficient than angiogenesis, has the potential to become a significant 
treatment option for vascular occlusive diseases.  
Despite major advances during the past years, a large discrepancy exists between 
the successful stimulation of arteriogenesis in experimental animal models and the 
disappointing outcome of recent clinical trials (van Royen 2005). For example, in 
the past decade, cardiovascular research particularly profited from knowledge 
gained from studying the possible inhibition of tumor angiogenesis (de novo 
formation of capillaries). Tumors with high rates of angiogenesis grow faster and 
usually become larger than those with low capillary density. The first clinical 
trials, therefore, were focused on influencing angiogenesis in cancer patients to 
inhibit further tumor growth or metastases by preventing angiogenesis and thus 
microcirculation in the tumor tissue. In ischemic vessel disease, the opposite of 
anti-angiogenesis is required. The hypoxia-driven sprouting of capillaries observed 
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in angiogenesis is fundamentally different from mechanical forces-mediated 
beneficial arteriogenesis in cardiovascular diseases (Grundmann 2007). The 
incorrect assumption of an equal efficacy of angiogenesis and arteriogenesis is a 
likely explanation for the negative outcome of the first clinical trials with the 
objective to stimulate collateral artery formation in cardiovascular disease (Heil 
2006). Blood flow to the regions distal to the site of occlusion is limited and oxygen 
supply is decreased. Therefore, the insights from anti-angiogenesis strategies were 
first used to enhance microcirculatory blood flow in the ischemic regions and 
improve clinical outcome of patients with stenotic vessel disease by promoting 
angiogenesis. Although not all turned out positive, various placebo-controlled trials 
have been initiated in recent years, indicating the potential of VEGF and FGFs to 
stimulate therapeutic angiogenesis (e.g. TRAFFIC, AGENT, VIVA), (Grines 2002; 
Lederman 2002; Simons 2002; Henry 2003). However, the focus on the capillary 
sprouting instead of stimulating growth of functional collateral arteries resulted in 
the negative outcome of therapeutic treatment of occlusive vascular disease.  
Intensive research on the basic mechanism of arteriogenesis is progressing towards 
first clinical trials with pro-arteriogenic compounds (Seiler 2001; Simons 2002; van 
Royen 2005) which by and large might facilitate arteriogenesis but would not 
induce it. Moreover, the processes regulating arterial enlargement are far from 
being understood and, especially, the translation from basic research to clinical 
practice remains challenging.  
The purpose of the present work was to delineate mechanisms responsible for the 
onset of arteriogenesis, particularly the mechanism of mechanosensitive 
expression of MCP-1 and its regulation of expression during this process. Moreover, 
the role of AP-1 activation was evaluated for the first time in the context of 
arteriogenesis.  
 
5.1. In vivo models of arteriogenesis – development of experimental 
tools 
Several animal models have been developed to outline factors that promote 
arteriogenesis (Scholz 2001). The first detailed studies of growing collateral vessels 
were performed in dog hearts, where the initial level of collateral development 
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seemed to predict the final development of collateral vessels after repetitive 
coronary occlusion (Yamamoto 1984). The events of collateral vessel growth 
observed in pig hearts are somewhat less clear than those in dogs. Due to their 
smaller size pre-existing porcine coronary collateral vessels are more difficult to 
define and to study serially (White 1992). In rabbit hindlimbs, pre-existing 
collateral arterioles have been identified in the thigh, and their transformation 
into collateral arteries upon artery occlusion is very similar to the growth process 
of canine coronary collateral vessels including neointima formation (Scholz 2000). 
In another model of arteriogenesis in rats, a pronounced remodelling of pre-
existing collateral thigh arterioles was observed within 7 days of femoral artery 
occlusion with subsequent neointima formation during the first three weeks 
(Hoefer 2001). And finally, in the mouse hindlimb, the growth of collateral arterial 
anastamoses observed after femoral artery ligation seems to be based on pre-
existing arteriolar connections that remodel into larger vessels with one to two 
layers of vascular smooth muscle cells forming the tunica media (Scholz 2002).    
Although differing in the spatiotemporal progression of the remodelling process, 
the common feature of these models is that the acute occlusion of a main feeding 
artery is employed to increase the blood flow in the collateral arterioles (Schaper 
2003). And despite the anatomical differences in these models, the primary 
importance of pre-existing collateral vessels for the natural revascularization 
process does not seem to be species-specific. The abrupt occlusion of a larger 
feeding artery, on the other hand, is one of the biggest hurdles of arteriogenesis 
research today – especially in terms of translational research – since in humans a 
relevant stenosis in a larger artery leading to compensation arteriogenesis, 
develops rather slowly over time.  
 
Nonetheless, in the present study a mouse ear artery ligation model (North 1958) 
was adapted to analyze the arteriogenic remodelling of collateral arterioles, 
thereby exploiting the easy accessibility and simplicity of the nearly two-
dimensional architecture of the ear vasculature. Occlusion of a distinct first order 
ear artery up-regulated the expression of intercellular adhesion molecule-1 (ICAM-
1) and monocyte chemotactic protein-1 (MCP-1) in the remodelling arterioles 
which could be identified by their corkscrew-like morphology after four to seven 
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days. Moreover, the classical mouse hindlimb ischemia model was used for 
comparison, in which an increased expression of ICAM-1 and MCP-1 was also 
observed 7 days after femoral artery occlusion. These findings correspond to 
earlier results obtained by Lee et al. (Lee 2004), where transcriptional profiling of 
the nonischemic adductor muscle in the thigh after artery excision had revealed an 
increased expression of MCP-1. They also resemble previously published 
observations made already in 1958 by North et al. that division of a blood vessel in 
the mouse ear is followed by a progressive enlargement of its collateral vessels 
(North 1958). 
 
5.2. MCP-1 orchestrates early steps in arteriogenesis 
Due to the predictability of collateral arteriolar enlargement in the mouse 
hindlimb, MCP-1 expression was analyzed already 24 hours after femoral artery 
occlusion. The observed significant up-regulation of MCP-1 expression during this 
period suggests that this chemokine may orchestrate rather early steps in the pro-
arteriogenic cascade. The release of MCP-1 is a prerequisite for the recruitment of 
monocytes to the arteriolar vessel wall which in turn initiate its transformation to 
a small conductance artery (Scholz 2000). After occlusion of an artery activated 
vascular cells of the collateral arterioles express MCP-1 and transfer it to their 
luminal cell surface where it is immobilized by proteoglycans (Heil 2007). Changes 
in the expression and conformation of adhesion molecules transform the collateral 
endothelium from a quiescent vessel layer into a “sticky” surface, now supporting 
attraction, adhesion and invasion of leukocytes. Consequently, expression of 
selectins, ICAM-1 and -2, and vascular cell adhesion molecules (VCAM-1) is 
increased (Scholz 2000). In addition, adhesion molecules undergo a fast 
conformational change and are clustered in so-called focal adhesion complexes.  
Attracted by MCP-1 and probably other chemoattractants, the monocyte binding to 
the collateral surface is mediated by intergrin receptors like Mac-1 and LFA-1 – 
counterparts of endothelial ICAM-1, -2 and VCAM-1. Monocytes, which mature to 
macrophages after entering the collateral vessel wall, have a central function in 
the induction of proliferation of vascular cells as well as in vascular cell 
remodelling. They function as micro-bioreactors and potently express proteases 
like matrix-metalloproteinases and urokinase-type plasminogen activator (uPA) 
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(Kusch 2002; Menshikov 2002) that weaken the cellular matrix. It was also observed 
that monocytes invade deeper layers of the collateral arteriolar wall and 
accumulate in perivascular clusters. 
Correspondingly, it has been shown earlier that local infusion of MCP-1 with the aid 
of an osmotic minipump into the proximal stump of an occluded femoral artery in 
rabbits markedly enhanced the recruitment of monocytes and the speed of 
arteriogenesis. In comparison to other growth factors, MCP-1 is the strongest pro-
arteriogenic peptide known (Ito 1997). In line with this, collateral artery growth 
and reperfusion in the ischemic tissue was diminished in MCP-1 and CC chemokine 
receptor 2 (CCR2) deficient mice (Heil 2004; Voskuil 2004).  
Interestingly, CCR2 - the primary receptor for MCP-1 – is not only expressed on 
monocytes but also on other leukocytes such as activated T-cells. This could mean 
that other leukocytes also recruited by this pathway which has been shown for 
lymphocytes are - similar to monocytes – leave the blood stream and localize in the 
vicinity of the growing arteriolar collaterals. Likewise, Stabile et al. (Stabile 2003) 
concluded that T-cells contribute to arteriogenesis by releasing chemoattractive 
factors, hence supporting monocyte recruitment and supporting their paracrine 
activity during arteriogenesis. 
 
5.3. Expression of MCP-1 is restricted mainly to smooth muscle cells  
Despite its importance for the initiation of arteriogenesis, only little is known 
about the mechanisms that control the expression of MCP-1 in this context. 
Therefore, a new experimental in situ model was established, where small second 
order branches of the mouse mesenteric artery were subjected to control (low 
flow) and pro-arteriogenic (high flow) conditions. Despite the common notion of 
MCP-1 being expressed in activated endothelial cells in the collateral arteriolar 
vessel wall during the onset of arteriogenesis (Scholz 2001), here the smooth 
muscle cells of the media were identified as the main source of MCP-1.  
Earlier studies were already pointing towards a localization of this chemokine to 
the smooth muscle cell layer of the remodelling collateral arterioles in the mouse 
hindlimb in vivo. Jost et al. observed that in mice treated with GM-CSF after 
ligation of the femoral artery expression of MCP-1 in the hindlimbs was restricted 
to cells constituting the vessel wall (media) after 3 days (Jost 2003).  
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Next, the question was addressed as to what triggers the expression of MCP-1 in 
the smooth muscle cells of the collateral arterioles undergoing remodelling. In this 
context, hemodynamic forces were characterized to be important for triggering 
arteriogenesis. Particularly, fluid shear stress has been intensively discussed as a 
molding force that probably initiates the cascade of events (Pipp 2004). It acts 
mainly on the endothelium which cushions the effect on the underlying smooth 
muscle cells that are further shielded by the internal elastic lamina. The related 
primarily but not exclusively force acting on the smooth muscle cell layer is 
circumferential wall strain (Schaper 1967; Scheel 1979). Its magnitude is much 
higher than that of fluid shear stress, and its increase in arteriogenesis is due to 
the initial volume-mediated distention (by Laplace’s law: dP = T/R, dP - 
transmural pressure difference, T- wall tension, R - and radius) and later, with the 
onset of active remodelling, by the thinning of the vessel wall (Scholz 2001). 
Proliferation of the smooth muscle cells normalizes circumferential wall strain 
again and probably contributes to the premature halt of the arteriogenic process 
(Scheel 1979).  
In this context, the observations made in this study suggest that of the two 
putative biomechanical determinants of arteriogenesis, FSS and CWS (Schaper 
2003; Heil 2004), the latter most likely is responsible for the increase in MCP-1 
expression, since changes in fluid shear stress can only be directly sensed by 
endothelial cells and an increase in fluid shear stress inhibited rather than 
augmented MCP-1 expression in both mouse and human endothelial cells.  
 
5.4. MCP-1 expression in vitro is induced only by cyclic stretch 
Further, the individual effects of laminar FSS and CWS on the expression of MCP-1 
were investigated in cultured cells. Exposing cultured endothelial cells to shear 
stress resulted in a decrease rather than an increase in MCP-1 expression both on 
the mRNA and protein level. This finding is in agreement with previous studies 
demonstrating that endothelial cell MCP-1 expression is in fact down-regulated in 
response to shear stress over a similar period (Shyy 1994). Likewise, up-regulation 
of expression of adhesion molecules (ICAM-1, VCAM-1 and E-selectin) critical for 
arteriogenesis has been shown to be inhibited in endothelial cells in response to 
laminar shear stress (Chiu 2003).  
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In contrast, exposure of cultured cells to cyclic stretch – a substitute of 
circumferential wall strain - resulted in a robust increase in MCP-1 expression both 
in cultured endothelial and smooth muscle cells. Moreover, the increase in MCP-1 
abundance in the supernatant of vascular smooth muscle cells was particularly 
striking. These results are in line with reports showing that cyclic stretch induces 
MCP-1 expression in cultured human endothelial cells (Okada 1998), and extend 
this finding also to vascular smooth muscle cells.  On the other hand, smooth 
muscle cells are also shown to be capable of up-regulating MCP-1 in response to 
certain pro-inflammatory cytokines (Cattaruzza 2002).  
Furthermore, the data support the hypothesis that cyclic or static stretch, as the 
result of an increase in circumferential wall strain, plays a decisive role in the 
expression of MCP-1 in the collateral arteriolar wall during the early phase of 
arteriogenesis. Conversely, the observations of this study question the view of 
arteriogenesis as a predominantly shear stress-mediated remodelling process. 
 
5.5. Up-regulation of MCP-1 expression depends on AP-1 activation 
As mentioned above, the mechanism by which MCP-1 expression is regulated during 
the onset of arteriogenesis it is not yet understood. Chemokine expression is 
regulated primarily at the level of gene transcription, although contributions by 
posttranscriptional mechanisms have also been reported (Villarete 1996; Martin 
1997; Olszewska-Pazdrak 1998). Previously it has been shown that the promoters of 
many chemokine genes, including interleukin-8 (IL-8), chemokine ligand 5 (CCL5 or 
RANTES), and MCP-1 contain binding sites for the redox-sensitive transcription 
factors activator protein-1 (AP-1) and nuclear factor-kB (NF-kB), both of which are 
thought to be involved in the transcriptional control of the aforementioned genes 
(Roebuck 1999).  
AP-1 and NF-kB are inducible transcription factors critical for the expression of 
many genes involved in the inflammatory response, including cytokines and 
adhesion molecules (Baeuerle 1994). Activator protein-1 is one of the main 
transcription factors activated by either ERK or JNK and plays a central role in a 
variety of cellular responses (Shaulian 2001). For example, in a series of 
experiments in rats, it has been shown that MAP kinases and AP-1 are significantly 
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activated in the hypertrophied heart, the balloon-injured artery and hypertensive 
vascular or renal tissue (Kim 2003). 
In the present study, the decoy oligodeoxynucleotide (dODN) technique (Mann 
2005) was employed to inhibit AP-1 activity in the cultured vascular cells and in 
the perfused branches of the mouse mesenteric artery. These short double-
stranded DNA sequences contain at least one consensus binding motif for AP-1 and 
even in the absence of surrounding DNA can bind the transcription factor in a 
highly specific manner (Dzau 2002). Taken together, the results revealed that 
stretch-induced MCP-1 expression in cultured smooth muscle cells is abolished in 
the presence of the AP-1 dODN. The same effect was observed in the branches of 
the mouse mesenteric artery perfused under pro-arteriogenic flow conditions.  
Moreover, these results are in line with previous reports where AP-1 has been 
shown to regulate the expression of many stress response genes, like connexin 43 
and MCP-1, including those associated with a pro-inflammatory phenotype of 
endothelial or smooth muscle cells (Wung 1997; Wu 2007).  
 
5.6. ROS formation is increased during arteriogenic remodelling  
A class of highly diffusible and ubiquitous molecules, termed reactive oxygen 
species (ROS), has previously been shown to function as signalling molecules 
leading to changes in gene expression during inflammatory episodes (Suzuki 1997) 
moreover, they can act as second messengers in cells exposed to various stimuli 
such as cytokines (Lo 1996). ROS encompass species such as the superoxide anion, 
hydrogen peroxide (H2O2), and hydroxyl radicals (Halliwell 1990). These highly 
reactive molecules are known to regulate many important cellular events, 
including gene expression (Lo 1995), transcription factor activation (Schreck 1991), 
DNA synthesis (Crawford 1988), and cell proliferation (Murrell 1990).  
Moreover, ROS have been shown to regulate chemokine gene expression. 
Particularly Satriano et al. have demonstrated that ROS act as second messengers 
for cytokine-induced MCP-1 expression (Satriano 1993). Although this redox 
regulation of MCP-1 expression appears to be at the transcriptional level and 
involves redox-sensitive transcription factors such as AP-1 and NF-kB, the exact 
mechanisms are unknown. On the other hand, in most cases, the activation of AP-1 
is triggered by an increase in the formation of ROS - another hallmark of vascular 
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stress responses (Shono 1996; Wung 1997), and inhibited by antioxidants such as 
the thiol compound N-acetyl cysteine (Pinkus 1996).   
In the present study, a marked increase in ROS formation was observed in smooth 
muscle cells upon exposure to cyclic stretch as well as in the isolated small 
arteries perfused under pro-arteriogenic conditions. Moreover, an increased 
formation of ROS associated with collateral arterioles undergoing remodelling was 
detected in the mouse hindlimb after femoral artery ligation. These findings 
support the hypothesis that the arteriogenesis-associated up-regulation of MCP-1 
expression in the arteriolar vessel wall most probably is triggered through a ROS – 
AP-1 pathway. This notion was verified by the finding that exposure of cultured 
smooth muscle cells to glucose oxidase lead to a rapid increase in MCP-1 mRNA 
confirming a role for the H2O2-generation in this context. 
 
5.7. AP-1 dependent regulation of arteriogenesis 
Collectively, the facts discussed so far suggest that in the early phase of 
arteriogenesis an increase in circumferential wall strain, hence stretch, triggers an 
increase in ROS formation in the arteriolar vessel wall which in turn leads to the 
translocation of AP-1 to the nucleus where it transactivates the MCP-1 gene. If this 
assumption is correct, then blocking of AP-1 activity in vivo should preclude the 
onset of arteriogenesis.  
To this end, the ear artery ligation model proved to be highly valuable due to the 
fact that it allowed administration of the AP-1 dODN in a dermal formulation. 
Topical application of this ointment resulted in an excellent penetration of the 
dODN through the skin into the wall of the ear blood vessels within 24 hours after 
the application. The resulting neutralization of AP-1 not only abrogated the 
arteriogenic response in the mouse ear 7 days post artery ligation, but also 
prevented the increase in MCP-1 expression. Furthermore, the infiltration of 
monocytes into the wall of the remodelling collateral arterioles was significantly 
decreased. The specificity of the AP-1 dODN approach was confirmed by the lack 
of effect of a mutant control ODN. Moreover, a dODN directed against the potent 
pro-inflammatory transcription factor signal transducer and activator of 
transcription-1 (STAT-1) also had no effect on the remodelling of the collateral 
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arterioles after ligation of the main artery. Thus, the AP-1 dependent adaptive 
response occurring in the remodelling collateral arterioles must be different from 
the more potent and potentially chronic inflammatory reaction which transcription 
factors such as STAT-1 are typically involved with.  
In contrast to many other forms of genetic manipulation both in cells in vitro and 
in intact tissues, transcription factor decoys have become a versatile tool for 
researches attempting both to define the role of various genes in normal and 
pathologic cell biology and to consider novel interventions. In just the past few 
years, for example, decoys have been studied in models of inflammation ranging 
from arthritis, sepsis, cerebral ischemia/reperfusion and transplant vasculopathy 
(NF-kappaB) to glomerulonephritis (E2F and AP-1), allergic airway reactivity and 
asthma (STAT-1, NF-kappaB) (Mann 2005). The most advanced clinical program 
involving the use of transcription factor decoys in human patients has been 
modification of the biology of venous bypass graft vasculopathy through intra-
operative administration of an E2F dODN (Ehsan 2001).  
In this study performed in the mouse ear artery ligation model, the application of 
dODNs in the dermal formulation not only showed a promising therapeutic 
approach, but also accentuated the pivotal role of AP-1 activation in the 
arteriogenic remodelling process.  
 
5.8. An outlook 
Even though MCP-1 is only one among many AP-1 target genes, the findings of this 
study corroborate that MCP-1 dependent monocyte recruitment is a rate-limiting 
step in arteriogenesis (Heil 2002). Moreover, they establish AP-1 as a critical 
modulator of MCP-1 expression in an as yet unrecognized context and point 
towards stretch-induced AP-1 dependent changes in gene expression in general as 
a decisive step in the initiation of arteriogenesis.  
These results are in line with previous reports where such AP-1 dependent changes 
in gene expression have also been shown to play a role in hypertension-induced 
arterial remodelling, where the activation of mitogen-activated protein (MAP) 
kinases was followed by c-fos and c-jun gene expression, hence activation of AP-1 
in vivo (Xu 1996). Moreover, accumulating evidence suggest that activation of AP-1 
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is a critical step in restenosis following angioplasty and stent placement (Buchwald 
2002).  
Therefore, a systematical comparison of the initial steps of these adaptive 
remodelling processes with that of arteriogenesis may ultimately lead to the 
identification of the main trigger of arteriogenesis and thus spur the development 
of a pro-arteriogenic therapy. 
Increasing the concentration of circulating monocytes is one potential target for 
therapeutic arteriogenesis nowadays, as there is a direct correlation between the 
number of circulating monocytes and arteriogenic remodelling (Heil 2002). Another 
approach would be to locally raise the number of monocytes, and one promising 
factor for this would be MCP-1 (Hoefer 2006). However, even though administered 
downstream of the abdominal aorta (i.e. into the collateral arteries of a murine 
hindlimb), MCP-1 significantly increased atherosclerotic plaque formation in the 
aortas of apolipoprotein E deficient mice (van Royen 2003), diminishing the chance 
that this potent pro-arteriogenic compound will make its way into clinical 
application.  
Other compounds, such as GM-CSF, have been shown to present anti-atherogenic 
properties as well as strong pro-arteriogenic actions. However, in the START trial 
van Royen et al. demonstrated that GM-CSF treatment does not have a beneficial 
effect in the patients with peripheral artery disease (van Royen 2005). For TGF, 
the effect of a pro-arteriogenic therapy on the underlying pathology, 
atherosclerosis, is not yet known and seems to be dose-dependent (Grundmann 
2007). Previous studies indicate that TGF has at least a neutral, if not inhibiting 
effect on atherosclerotic plaque formation (Lutgens 2002).  
The ideal candidate molecule should have a pro-arteriogenic and anti-
atherosclerotic effect at the same time, stimulate collateral artery growth at any 
rate independent of the history of the patient and the affected vascular bed, and 
it should be easy to administer. Thus, by enhancing the current mechanistic 
knowledge in this field, the observations of this study may contribute to the 
understanding of a well-orchestrated and self-limiting arterial remodelling process 
that may eventually be exogenously induced for therapeutic purposes.  
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6. Summary 
Occlusive vascular diseases represent the most frequent cause of death in 
industrialized nations. Treatment of the end-stage of these diseases such as 
myocardial infarction, stroke, peripheral artery disease and others is usually 
limited to interventions such as angioplasty, bypass surgery or limb amputation. An 
alternative approach to restore blood flow to the ischemic tissue can be the 
therapeutic induction and/or enhancement of the endogenous collateral 
circulation (arteriogenesis), bypassing the site of stenosis and protecting the 
downstream tissue from ischemic injury. Since biomechanical forces have been 
implicated in the initiation of arteriogenesis, their impact on the remodelling 
process during the onset of arteriogenesis and on the mechanosensitive expression 
of a pivotal pro-arteriogenic molecule, monocyte chemoattractant protein-1 (MCP-
1), was investigated in the present study. MCP-1 governs the recruitment of 
circulating monocytes to the wall of the remodeling collateral arterioles – an 
essential step in the initiation of collateral artery formation. 
Employing two different in vivo mouse models – the hindlimb ischemia model and a 
novel ear artery ligation model – revealed that MCP-1 expression is significantly 
increased in collateral arterioles undergoing arteriogenesis already 24 hours after 
its onset. To define the mechanism triggering MCP-1 expression, an in situ 
perfusion model of small mouse arteries was established, mimicking the pro-
arteriogenic perfusion conditions. Subsequent gene expression analyses showed 
that MCP-1 expression is predominantly up-regulated in the smooth muscle cells of 
these arterial segments which solely sense changes in circumferential wall strain or 
stretch. Further analyses of cultured endothelial and smooth muscle cells 
confirmed that elevated levels of shear stress do not up-regulate MCP-1 expression 
in these cells while application of cyclic stretch to both cell types resulted in a 
robust increase in MCP-1 expression both on the mRNA and especially on the 
protein level.  
Inhibition of the mechanosensitive transcription factor activator protein-1 (AP-1) 
by employing the decoy oligodeoxynucleotide (dODN) technique abolished the 
stretch-induced expression of MCP-1 in the cultured cells as well as in the isolated 
perfused segments of the mouse mesenteric artery.  
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Further analyses revealed an increased ROS formation in the cultured smooth 
muscle cells upon exposure to cyclic stretch as well as in the second order 
branches of mouse mesenteric artery perfused under pro-arteriogenic flow 
conditions in situ. Inhibition of ROS production by the ROS scavenger Idebenone 
abolished stretch-induced MCP-1 expression.  
Finally, topical application of the AP-1 dODN to the mouse ear after arterial 
occlusion completely abrogated remodelling of the collateral arterioles through 
down-regulating MCP-1 expression and monocyte recruitment. Administration of a 
dODN against transcriptional factor signal transducer and activator of 
transcription-1 (STAT-1) in the same model did not affect the arteriogenic 
remodelling process pointing towards a more specific role of AP-1 signaling to the 
nucleus therein.  
In summary, the present study establishes the ear artery ligation model of the 
mouse as a new experimental tool to investigate adaptive arteriolar remodelling 
processes in vivo. Furthermore, the data point towards a stretch-induced AP-1 
mediated rise in MCP-1 expression in vascular smooth muscle cells as a critical 
determinant for the initiation of arteriogenesis. Conversely, the observations of 
this study question the view of arteriogenesis as a predominantly shear stress-
mediated remodelling process and contribute to the deeper understanding of a 
well-orchestrated arterial remodelling process that may eventually be exogenously 
induced for therapeutic purposes.  
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